N/A N=20 Cerebral Edema in Pediatric Diabetic Ketoacidosis
Diabetic Ketoacidosis
Primary: Cerebral Edema Measured by MR Imaging (Apparent Diffusion Coefficient) — 36; 48 mm^2/sec
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=57 Treating Brain Swelling in Pediatric Cerebral Malaria
Malaria, Cerebral
Primary: Number of Participants Who Died — 5; 5; 5 Participants
Early Phase 1 N=28 Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage
Intracerebral Hemorrhage · Cerebral Edema · Stroke Hemorrhagic
Primary: Number of Participants With Clinically Significant Cardiac Events — 3; 0; 0 Participants — p=0.0427
Phase 1 N=7 Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study
Cerebral Hemorrhage · Cerebral Edema · Intracerebral Hemorrhage
Primary: Patient Tolerance of Conivaptan — 0; 0; 1; 0 Participants
Phase 3 N=200 XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Brain Edema · Brain Tumor
Primary: The Proportion of Patients in Each Treatment Group Who Are Responders at Week 2 and Continue to be Responders at Week 5 — 57; 46 participants
N/A N=460 Cerebral Autoregulation Monitoring During Cardiac Surgery
Thoracic Surgery · Cardiopulmonary Bypass
Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…
N/A N=15 Cerebral Blood Flow During Hemodialysis
Haemodialysis-induced Symptom
Primary: Change in CBF From Baseline (Before Start of the Hemodialysis Study Session), at 20 Minutes, and at the End of the Hemodialysis Study Session, Measured by [15O]H2OPET-CT…
Phase 2 N=96 Normobaric Hyperoxia for Intracerebral Hemorrhage
Normobaric Hyperoxia · Intracerebral Hemorrhage
Primary: Percentage of Patients With mRS 0-3 — 39; 27 Participants
N/A N=60 Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy
Brain Neoplasms · Surgery · Hyperemia
Primary: Mean Blood Flow Velocity in Middle Cerebral Artery — 63.7; 61.8 cm/s — p=0.554
N/A N=34 Cerebral Blood Flow and Childhood Obstructive Sleep Apnea
Obstructive Sleep Apnea Syndrome
Primary: Change in Cerebral Blood Flow (CBF) at Baseline Between Obstructive Sleep Apnea Syndrome (OSAS) and Controls — 184; 209 percentage of change from baseline
Phase 3 N=200 Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Anemia · Traumatic Brain Injury
Primary: Glasgow Outcome Scale — 17; 17; 34; 37 participants — p=.01
Phase 3 N=1,389 Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis
Cerebral Edema · Diabetic Ketoacidosis
Primary: the Number of Participants With Glasgow Coma Score (GCS) < 14 Within the First 24 Hours of Treatment for Diabetic Ketoacidosis (DKA) — 10; 11; 11; 16 Participants — p=0.34
Phase 2 N=43 A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)
Carcinomatous Edema
Primary: Change in Body Weight From Baseline at Final IMP Administration — -0.69; -0.34; -1.13; 0.70 Kg
Phase 2 N=81 Bolus of Saline in Stroke
Ischemic Stroke
Primary: The Percentage of Change in Optical Cerebral Blood Flow (oCBF) During Bolus Normal Saline Compared to Baseline, as Measured by Diffuse Correlation Spectroscopy (DCS)…
N/A N=96 Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Traumatic Brain Injury
Primary: Time ICP >20 — 1.7; .9 Hours
N/A N=23 Intracranial Pressure in Experimental Models of Headache
High Altitude Headache
Primary: Change in Optic Nerve Sheath Diameter by Ultrasonography — 0.02; 0.02 mm — p=0.98
Phase 2 N=104 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
Cirrhosis
Primary: Body Weight (Amount of Change) — -0.68; -2.31; -1.88; -1.67 Kg — p=0.3167
Phase 4 N=11 Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm
Subarachnoid Hemorrhage, Aneurysmal · Vasospasm, Cerebral
Primary: Number of Participants Who Develop Delayed Cerebral Vasospasm — 2 Participants
Phase 1 N=20 Reperfusion With Cooling in Cerebral Acute Ischemia
Stroke, Acute
Primary: Number of Participants With Reperfusion Injury Hemorrhagic Transformation — 3 participants
Phase 2 N=122 Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI)
Severe Traumatic Brain Injury
Primary: Fraction of Time That Brain Oxygen Levels Are Below the Critical Threshold of 20 mm Hg . — 0.15; 0.44 Proportion
Phase 2 N=6 Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access
Stroke · Intracranial Hypotension · Cerebral Edema
Primary: Number of Subjects With Tissue Damage — 0 Participants
Phase 2 N=18 Hyperbaric Treatment of Traumatic Brain Injury (TBI)
Traumatic Brain Injury
Primary: Number of Participants With Improved Cerebral Perfusion — 8 Participants
N/A N=68 Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients
Intracranial Aneurysm · Brain Edema · Scoliosis
Primary: Number of ICU Stays Greater Than 1.5 Days — 13; 20 Number of ICU Stays greater that 1.5 Day
N/A N=14 A Pilot Study of Optic Nerve Ultrasound Following Cardiopulmonary Bypass
Congenital Heart Disease · Congenital Heart Defect
Primary: Optic Nerve Sheath Diameter — 4.0; 3.6; 4.2; 3.5 millimeters
N/A N=49 The Efficacy of Normobaric Oxygen on Chronic Cerebral Ischemia
Normobaric Oxygen · Cerebral Ischemia
Primary: The Fronto-central Theta Absolute Power Change Rate — 0.14; -0.12 ratio
N/A N=5 Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension
Intracranial Hypotension
Primary: Intracranial Pressure Measurements Estimated by the MRICP Technique. — 6.5 cm H20
Phase 2 N=36 Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…
Phase 3 N=35 Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
Hypertension · Hemorrhage
Primary: Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine — 5.5 minutes
N/A N=100 Cerebral Oxygenation in Total Hip Arthroplasty Patients
Cerebral Oxygen Desaturation · Post-operative Delirium
Primary: Oxygen Desaturation Incidences — 4 Participants
N/A N=100 Optic Nerve Sheath Diameter (ONSD) With the Raised PCO2 and Internal Jugular Venous Occlusion
Elevated Intracranial Pressure (ICP)
Primary: Changes in ONSD in mm With Changes in ICP in Healthy Volunteers. — 4.2 mm